EZH2 and ovarian carcinoma: EZH2 inhibition has been shown to increase the infiltration of CD8+ T cells in ovarian cancer models [43], and comparisons of tumor biopsy samples obtained prior to and during Tazemetostat revealed a substantial increase in intra-tumoral and stromal infiltrates of CD8+ cytotoxic and FOXP3+ regulatory T cells, together with an enhanced expression of the PD-1 and LAG3 immune-checkpoint proteins on T cells [39].